Abstract
End-stage renal disease (ESRD) is a late diagnosis. Its prevalence is rapidly increasing worldwide. Although various management techniques exist, they all require access routes. The arteriovenous fistula (AVF) is the vascular access of choice for regular and prolonged hemodialysis sessions. Studies have shown that an AVF saves patients money. In our context, we found no data in the literature on the cost of AVF and the lump-sum cost. The aim of this study was to determine the average costs of AVF and lump-sum costs, and to describe patients’ coping strategies in relation to these costs.
Methods We conducted a cross-sectional study in the three public hemodialysis units of the city of Ouagadougou, Burkina Faso. Hemodialysis patients suffering from chronic renal failure, hospitalized or not, minors or adults having given their consent (assent) were included in the study.
Results A total of 290 patients ranging in age from 12 to 82 years participated in the study. Almost half the patients (47.5%) had no income. More than half the patients had undergone fistula repair privately. Hypertension and diabetes were the pathologies most frequently associated with end-stage renal disease in this study, with 77% and 16.90% respectively. The average cost of a fistula was 260,798 Fcfa, while the average cost of a package was 506,459 Fcfa. To cope with these costs, some patients resorted to selling goods (means of subsistence) in 4.83%, borrowing, bartering and others begging.
Conclusion The average cost of arteriovenous fistula and the fixed fee for haemodialysis remain an economic barrier for patients and families to haemodialysis in Burkina Faso. More than half of all patients have their fistulas done in the private sector, which costs twice as much as the public sector. Training providers working in public haemodialysis units to perform arteriovenous fistula is necessary to reduce this cost for patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As with any study involving human subjects, this study was submitted to and approved by the Burkina Faso Health Research Ethics Committee (CERS) (N°2020-8-165). Participants were informed about the study and gave their informed consent before answering any questions.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data supporting the results of this study are available from [Amadou Oury Toure], but restrictions apply to the availability of these data and are therefore not publicly accessible, as our research group is working on further analyses using the same data which will then be submitted for publication. However, these data are available on reasonable request from the corresponding author [Amadou Oury Touré].
